RMOC briefing on adalimumab – July 2018

This third briefing paper is provided through the RMOC system.  It forms the July edition of a series of briefings on best value biological medicines.  The briefing summarises: information about imminent patient information material from NHS England; details of a toolkit to support implementation of best value biological medicines; a procurement update; and progress to date in planning for the patent expiry of the originator adalimumab product Humira® in October 2018.

AdalimumabBiosimilar medicineNewsRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resources

Attachments